Cargando…

Plasma Proteomics in Healthy Subjects with Differences in Tissue Glucocorticoid Sensitivity Identifies A Novel Proteomic Signature

Significant inter-individual variation in terms of susceptibility to several stress-related disorders, such as myocardial infarction and Alzheimer’s disease, and therapeutic response has been observed among healthy subjects. The molecular features responsible for this phenomenon have not been fully...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicolaides, Nicolas C., Makridakis, Manousos, Stroggilos, Rafael, Lygirou, Vasiliki, Koniari, Eleni, Papageorgiou, Ifigeneia, Sertedaki, Amalia, Zoidakis, Jerome, Charmandari, Evangelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773719/
https://www.ncbi.nlm.nih.gov/pubmed/35052863
http://dx.doi.org/10.3390/biomedicines10010184
_version_ 1784636163890348032
author Nicolaides, Nicolas C.
Makridakis, Manousos
Stroggilos, Rafael
Lygirou, Vasiliki
Koniari, Eleni
Papageorgiou, Ifigeneia
Sertedaki, Amalia
Zoidakis, Jerome
Charmandari, Evangelia
author_facet Nicolaides, Nicolas C.
Makridakis, Manousos
Stroggilos, Rafael
Lygirou, Vasiliki
Koniari, Eleni
Papageorgiou, Ifigeneia
Sertedaki, Amalia
Zoidakis, Jerome
Charmandari, Evangelia
author_sort Nicolaides, Nicolas C.
collection PubMed
description Significant inter-individual variation in terms of susceptibility to several stress-related disorders, such as myocardial infarction and Alzheimer’s disease, and therapeutic response has been observed among healthy subjects. The molecular features responsible for this phenomenon have not been fully elucidated. Proteomics, in association with bioinformatics analysis, offer a comprehensive description of molecular phenotypes with clear links to human disease pathophysiology. The aim of this study was to conduct a comparative plasma proteomics analysis of glucocorticoid resistant and glucocorticoid sensitive healthy subjects and provide clues of the underlying physiological differences. For this purpose, 101 healthy volunteers were given a very low dose (0.25 mg) of dexamethasone at midnight, and were stratified into the 10% most glucocorticoid sensitive (S) (n = 11) and 10% most glucocorticoid resistant (R) (n = 11) according to the 08:00 h serum cortisol concentrations determined the following morning. One month following the very-low dose dexamethasone suppression test, DNA and plasma samples were collected from the 22 selected individuals. Sequencing analysis did not reveal any genetic defects in the human glucocorticoid receptor (NR3C1) gene. To investigate the proteomic profile of plasma samples, we used Liquid Chromatography–Mass Spectrometry (LC-MS/MS) and found 110 up-regulated and 66 down-regulated proteins in the S compared to the R group. The majority of the up-regulated proteins in the S group were implicated in platelet activation. To predict response to cortisol prior to administration, a random forest classifier was developed by using the proteomics data in order to distinguish S from R individuals. Apolipoprotein A4 (APOA4) and gelsolin (GSN) were the most important variables in the classification, and warrant further investigation. Our results indicate that a proteomics signature may differentiate the S from the R healthy subjects, and may be useful in clinical practice. In addition, it may provide clues of the underlying molecular mechanisms of the chronic stress-related diseases, including myocardial infarction and Alzheimer’s disease.
format Online
Article
Text
id pubmed-8773719
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87737192022-01-21 Plasma Proteomics in Healthy Subjects with Differences in Tissue Glucocorticoid Sensitivity Identifies A Novel Proteomic Signature Nicolaides, Nicolas C. Makridakis, Manousos Stroggilos, Rafael Lygirou, Vasiliki Koniari, Eleni Papageorgiou, Ifigeneia Sertedaki, Amalia Zoidakis, Jerome Charmandari, Evangelia Biomedicines Article Significant inter-individual variation in terms of susceptibility to several stress-related disorders, such as myocardial infarction and Alzheimer’s disease, and therapeutic response has been observed among healthy subjects. The molecular features responsible for this phenomenon have not been fully elucidated. Proteomics, in association with bioinformatics analysis, offer a comprehensive description of molecular phenotypes with clear links to human disease pathophysiology. The aim of this study was to conduct a comparative plasma proteomics analysis of glucocorticoid resistant and glucocorticoid sensitive healthy subjects and provide clues of the underlying physiological differences. For this purpose, 101 healthy volunteers were given a very low dose (0.25 mg) of dexamethasone at midnight, and were stratified into the 10% most glucocorticoid sensitive (S) (n = 11) and 10% most glucocorticoid resistant (R) (n = 11) according to the 08:00 h serum cortisol concentrations determined the following morning. One month following the very-low dose dexamethasone suppression test, DNA and plasma samples were collected from the 22 selected individuals. Sequencing analysis did not reveal any genetic defects in the human glucocorticoid receptor (NR3C1) gene. To investigate the proteomic profile of plasma samples, we used Liquid Chromatography–Mass Spectrometry (LC-MS/MS) and found 110 up-regulated and 66 down-regulated proteins in the S compared to the R group. The majority of the up-regulated proteins in the S group were implicated in platelet activation. To predict response to cortisol prior to administration, a random forest classifier was developed by using the proteomics data in order to distinguish S from R individuals. Apolipoprotein A4 (APOA4) and gelsolin (GSN) were the most important variables in the classification, and warrant further investigation. Our results indicate that a proteomics signature may differentiate the S from the R healthy subjects, and may be useful in clinical practice. In addition, it may provide clues of the underlying molecular mechanisms of the chronic stress-related diseases, including myocardial infarction and Alzheimer’s disease. MDPI 2022-01-16 /pmc/articles/PMC8773719/ /pubmed/35052863 http://dx.doi.org/10.3390/biomedicines10010184 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nicolaides, Nicolas C.
Makridakis, Manousos
Stroggilos, Rafael
Lygirou, Vasiliki
Koniari, Eleni
Papageorgiou, Ifigeneia
Sertedaki, Amalia
Zoidakis, Jerome
Charmandari, Evangelia
Plasma Proteomics in Healthy Subjects with Differences in Tissue Glucocorticoid Sensitivity Identifies A Novel Proteomic Signature
title Plasma Proteomics in Healthy Subjects with Differences in Tissue Glucocorticoid Sensitivity Identifies A Novel Proteomic Signature
title_full Plasma Proteomics in Healthy Subjects with Differences in Tissue Glucocorticoid Sensitivity Identifies A Novel Proteomic Signature
title_fullStr Plasma Proteomics in Healthy Subjects with Differences in Tissue Glucocorticoid Sensitivity Identifies A Novel Proteomic Signature
title_full_unstemmed Plasma Proteomics in Healthy Subjects with Differences in Tissue Glucocorticoid Sensitivity Identifies A Novel Proteomic Signature
title_short Plasma Proteomics in Healthy Subjects with Differences in Tissue Glucocorticoid Sensitivity Identifies A Novel Proteomic Signature
title_sort plasma proteomics in healthy subjects with differences in tissue glucocorticoid sensitivity identifies a novel proteomic signature
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773719/
https://www.ncbi.nlm.nih.gov/pubmed/35052863
http://dx.doi.org/10.3390/biomedicines10010184
work_keys_str_mv AT nicolaidesnicolasc plasmaproteomicsinhealthysubjectswithdifferencesintissueglucocorticoidsensitivityidentifiesanovelproteomicsignature
AT makridakismanousos plasmaproteomicsinhealthysubjectswithdifferencesintissueglucocorticoidsensitivityidentifiesanovelproteomicsignature
AT stroggilosrafael plasmaproteomicsinhealthysubjectswithdifferencesintissueglucocorticoidsensitivityidentifiesanovelproteomicsignature
AT lygirouvasiliki plasmaproteomicsinhealthysubjectswithdifferencesintissueglucocorticoidsensitivityidentifiesanovelproteomicsignature
AT koniarieleni plasmaproteomicsinhealthysubjectswithdifferencesintissueglucocorticoidsensitivityidentifiesanovelproteomicsignature
AT papageorgiouifigeneia plasmaproteomicsinhealthysubjectswithdifferencesintissueglucocorticoidsensitivityidentifiesanovelproteomicsignature
AT sertedakiamalia plasmaproteomicsinhealthysubjectswithdifferencesintissueglucocorticoidsensitivityidentifiesanovelproteomicsignature
AT zoidakisjerome plasmaproteomicsinhealthysubjectswithdifferencesintissueglucocorticoidsensitivityidentifiesanovelproteomicsignature
AT charmandarievangelia plasmaproteomicsinhealthysubjectswithdifferencesintissueglucocorticoidsensitivityidentifiesanovelproteomicsignature